Full text
Earnings transcript
Read the complete earnings call transcript.
DGX
Quest Diagnostics Incorporated
$198.02
0.33
(0.17%)
| Exchange: | NYSE |
| Market Cap: | 22.028B |
| Shares Outstanding: | 117.452M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | James E. Davis | |||||
| Full Time Employees: | 55000 | |||||
| Address: |
| |||||
| Website: | https://www.questdiagnostics.com |
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 9,252,000 | 9,872,000 | 11,035,000 |
| Gross Profit | 3,069,000 | 3,244,000 | 3,523,000 |
| EBITDA | 1,732,000 | 1,894,000 | 2,194,000 |
| Operating Income | 1,262,000 | 1,346,000 | 1,603,000 |
| Net Income | 854,000 | 871,000 | 992,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 14,022,000 | 16,153,000 | 16,225,000 |
| Total Liabilities | 7,604,000 | 9,257,000 | 9,055,000 |
| Total Stockholders Equity | 6,307,000 | 6,778,000 | 7,170,000 |
| Total Debt | 5,498,000 | 7,087,000 | 6,382,000 |
| Cash and Cash Equivalents | 686,000 | 549,000 | 420,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 1,272,000 | 1,334,000 | 1,886,000 |
| Capital Expenditure | -408,000 | -425,000 | -527,000 |
| Free Cash Flow | 864,000 | 909,000 | 1,359,000 |
| Net Income | 908,000 | 921,000 | 1,046,000 |
| Net Change in Cash | 371,000 | -137,000 | -129,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2029 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 13,132,615.685 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 13,657,010.598 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 13,429,379.247 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 2,770,615.302 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 2,881,247.990 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 2,833,224.129 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 1,525,392.663 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 1,605,115.294 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 1,570,509.043 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 2,316,085.606 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 2,408,568.592 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 2,368,423.224 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 13.900 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 14.200 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 13.500 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 5 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Financial Performance: DGX demonstrates consistent revenue and net income growth as reflected in recent income statements, supported by strong operating cash flow and free cash flow figures from cash flow statements. This indicates operational efficiency and financial stability, appealing to investors seeking reliable returns.
- Favorable Valuation Metrics: The current price-to-earnings (P/E) ratio and price-to-sales (P/S) ratio from key metrics suggest DGX is reasonably valued compared to industry averages, providing a potential value investment opportunity. Forward P/E ratios indicate stable or improving market expectations for future earnings.
- Strong Balance Sheet: Balance sheet data shows a healthy current ratio and quick ratio, indicating good liquidity to cover short-term obligations. Additionally, a manageable debt-to-equity ratio suggests prudent financial leverage, reducing risk exposure.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates DGX intrinsic value between $118.37 – $144.20 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about DGX valuation
Is Quest Diagnostics Incorporated (DGX) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Quest Diagnostics Incorporated (DGX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is DGX a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether DGX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is DGX’s P/E ratio?
You can see DGX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for DGX?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is DGX a good long-term investment?
Whether DGX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
DGX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.17
Trading Metrics:
| Open: | 196.66 | Previous Close: | 197.69 | |
| Day Low: | 196.06 | Day High: | 199.14 | |
| Year Low: | 157.2 | Year High: | 213.5 | |
| Price Avg 50: | 197.87 | Price Avg 200: | 184.35 | |
| Volume: | 346825 | Average Volume: | 969318 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeDGX full analysis
Welcome to MARKETSNAP’s SWOT analysis for Quest Diagnostics, also known by its ticker DGX. If you’re a long-term investor looking to build wealth through smart stock picks, you’re in the right place. Today, we’re diving deep into Quest Diagnostics, a key player in the healthcare diagnostics space, to break down its strengths, weaknesses, opportunities, and threats. I’ll also sprinkle in some recent updates and financial insights to keep things interesting and actionable for your portfolio. So, let’s get started! Quick…
Could not create stock discussion for DGX
